Answers are grounded in this paper and cite their sources.
Systematic review demonstrates improved pCR rates with pertuzumab in HER2+ breast cancer, suggesting wider adoption of dual HER2 blockade.
In real-world settings, adding pertuzumab to neoadjuvant therapy significantly improves pCR rates in early-stage HER2+ breast cancer, aligning with RCT evidence. These findings support the broader adoption of dual HER2 blockade and highlight the need for further prospective real-world studies to refine treatment strategies for specific patient subgroups.
No takes yet. Share an insight, caveat, or question.
Matsas et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: